Barr Laboratories (BRL-N) Stock Predictions - Stockchase
WATCH LIST
11
Barr Laboratories (BRL-N)

ON STOCKCHASE SINCE Apr 2002

biotechnology/pharmaceutical

Barr Laboratories

BRL-N

0 watching          
Join the Discussion

Barr Laboratories (BRL-N) SAVE Dec, 31, 1969, 7:00 pm

0.00 0 (100%)

This company is not ACTIVE.

What the experts are saying about BRL-N



  • All
  • Filtered
Signal Opinion Expert
PAST TOP PICK
Barr Laboratories(BRL-N) 

October 24, 2006

(A Top Pick Sept 26/05. Down 7%.) Still likes. Down because the Wal-Mart announcement of putting price pressures on generics. Very innovative company, introducing lots of new products. Acquiring a European company to increase penetration into Europe.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
(A Top Pick Sept 26/05. Down 7%.) Still likes. Down because the Wal-Mart announcement of putting price pressures on generics. Very innovative company, introducing lots of new products. Acquiring a European company to increase penetration into Europe.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Laura Wallace

Managing D, Coleford Investment ...

Price Price
$52.470
Owned Owned
Yes

PAST TOP PICK
Barr Laboratories(BRL-N) 

August 14, 2006

(A Top Pick Sept 26/05. Up 10%.) Still likes and is continuing to buy it here. The big news is the approval of their oral contraceptive.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
(A Top Pick Sept 26/05. Up 10%.) Still likes and is continuing to buy it here. The big news is the approval of their oral contraceptive.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Laura Wallace

Managing D, Coleford Investment ...

Price Price
$52.320
Owned Owned
Yes

BUY
Barr Laboratories(BRL-N) 

July 20, 2006

Has come off sharply but she is still buying. There were delays in the FDA in getting some of its drugs approved. Earnings will continue to be delivered and thinks their drug will be approved. Good value.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Has come off sharply but she is still buying. There were delays in the FDA in getting some of its drugs approved. Earnings will continue to be delivered and thinks their drug will be approved. Good value.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Laura Wallace

Managing D, Coleford Investment ...

Price Price
$46.370
Owned Owned
Yes

PAST TOP PICK
(A Top Pick Mar 15/06. Down 22%.) Lowered its guidance by $0.01 and also received a letter from the FDA denying them an extension on a patent. Feels they can continue to grow earnings in the 15/20% range. In a good buying range now.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
(A Top Pick Mar 15/06. Down 22%.) Lowered its guidance by $0.01 and also received a letter from the FDA denying them an extension on a patent. Feels they can continue to grow earnings in the 15/20% range. In a good buying range now.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Laura Wallace

Managing D, Coleford Investment ...

Price Price
$49.730
Owned Owned
Yes

TOP PICK
Generic drug manufacturer. Earnings are growing in the 20/25% range. Generics are the beneficiaries of the push to control the accelerating healthcare costs in the US. Have a good record of acquiring new generics and delivering them in a very cost effective way. No debt on the balance sheet. Great operating margins in the 35/38% range.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Generic drug manufacturer. Earnings are growing in the 20/25% range. Generics are the beneficiaries of the push to control the accelerating healthcare costs in the US. Have a good record of acquiring new generics and delivering them in a very cost effective way. No debt on the balance sheet. Great operating margins in the 35/38% range.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Laura Wallace

Managing D, Coleford Investment ...

Price Price
$60.410
Owned Owned
Yes

TOP PICK
Barr Laboratories(BRL-N) 

March 15, 2006

Barr Pharma is a generic manufacturer. Good match with a large cap drug company. Barr is a very good company. Strong balance sheet. Started buying at $47-48 range and are still buying.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Barr Pharma is a generic manufacturer. Good match with a large cap drug company. Barr is a very good company. Strong balance sheet. Started buying at $47-48 range and are still buying.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Laura Wallace

Managing D, Coleford Investment ...

Price Price
$63.380
Owned Owned
Yes

TOP PICK
Barr Laboratories(BRL-N) 

September 26, 2005

A generic manufacturer, so unlike big pharmas that suffer when things come off, they actually benefit. Just picked up Allegra which is coming off patent. A great growth vehicle with a lot of drugs coming off patent in the next several years. Great exposure in women's health products.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
A generic manufacturer, so unlike big pharmas that suffer when things come off, they actually benefit. Just picked up Allegra which is coming off patent. A great growth vehicle with a lot of drugs coming off patent in the next several years. Great exposure in women's health products.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Laura Wallace

Managing D, Coleford Investment ...

Price Price
$52.220
Owned Owned
Yes

BUY
Barr Laboratories(BRL-N) 

July 19, 2005

Prefers the US health care stocks as they are much larger and much more seasoned. The big pharma has been a very difficult area. A generic manufacturer. As more and more drugs come off patent, this is a good way to take advantage of the increasing demand for drugs.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Prefers the US health care stocks as they are much larger and much more seasoned. The big pharma has been a very difficult area. A generic manufacturer. As more and more drugs come off patent, this is a good way to take advantage of the increasing demand for drugs.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Laura Wallace

Managing D, Coleford Investment ...

Price Price
$47.550
Owned Owned
Yes

TOP PICK
Barr Laboratories(BRL-N) 

June 20, 2005

A generic drug manufacturer. Going to continue to grow at 15/20% over the next 3/5 years. There's a number of drugs coming off patent over the next 2/3 years and this company is probably the best positioned to benefit. Good price.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
A generic drug manufacturer. Going to continue to grow at 15/20% over the next 3/5 years. There's a number of drugs coming off patent over the next 2/3 years and this company is probably the best positioned to benefit. Good price.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Laura Wallace

Managing D, Coleford Investment ...

Price Price
$48.920
Owned Owned
Yes

BUY on WEAKNESS
Barr Laboratories(BRL-N) 

July 17, 2003

Generic drugs is a great sector. Accumulate on a gradual basis.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Generic drugs is a great sector. Accumulate on a gradual basis.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Brad Willock

Vice Presi, RBC Asset Management...

Price Price
$63.730
Owned Owned
Unknown

DON'T BUY
Barr Laboratories(BRL-N) 

April 10, 2002

Health sector has been under a lot of pressure. Prefers specialty pharmaceuticals.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Health sector has been under a lot of pressure. Prefers specialty pharmaceuticals.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Noah Blackstein

Prtf Mngr , Dynamic Funds...

Price Price
$67.650
Owned Owned
Unknown

Showing 1 to 11 of 11 entries
Successfully Saved Company
Successfully Saved Company
4+
JOIN THE DISCUSSION
4 comments in the last 7 days